PT867178E - Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono - Google Patents

Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono

Info

Publication number
PT867178E
PT867178E PT98102355T PT98102355T PT867178E PT 867178 E PT867178 E PT 867178E PT 98102355 T PT98102355 T PT 98102355T PT 98102355 T PT98102355 T PT 98102355T PT 867178 E PT867178 E PT 867178E
Authority
PT
Portugal
Prior art keywords
gaba
sleep disorders
alostericos
agonists
treatment
Prior art date
Application number
PT98102355T
Other languages
English (en)
Inventor
Marike Lancel
Original Assignee
Max Planck Ges Zur Forderung W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT867178(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Ges Zur Forderung W filed Critical Max Planck Ges Zur Forderung W
Publication of PT867178E publication Critical patent/PT867178E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PT98102355T 1995-07-13 1996-07-10 Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono PT867178E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19525598A DE19525598C2 (de) 1995-07-13 1995-07-13 Schlafmittel

Publications (1)

Publication Number Publication Date
PT867178E true PT867178E (pt) 2002-04-29

Family

ID=7766768

Family Applications (3)

Application Number Title Priority Date Filing Date
PT98102356T PT867184E (pt) 1995-07-13 1996-07-10 Utilizacao de tiagabina para o tratamento de desordens do sono
PT98102355T PT867178E (pt) 1995-07-13 1996-07-10 Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
PT96925704T PT840601E (pt) 1995-07-13 1996-07-10 Thip para o tratamento de desordens do sono

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT98102356T PT867184E (pt) 1995-07-13 1996-07-10 Utilizacao de tiagabina para o tratamento de desordens do sono

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT96925704T PT840601E (pt) 1995-07-13 1996-07-10 Thip para o tratamento de desordens do sono

Country Status (12)

Country Link
US (1) US5929065A (pt)
EP (3) EP0867184B1 (pt)
JP (3) JP3754705B2 (pt)
AT (3) ATE207349T1 (pt)
AU (1) AU723954B2 (pt)
CA (1) CA2226582C (pt)
CL (1) CL2003002785A1 (pt)
DE (4) DE19525598C2 (pt)
DK (3) DK0867184T3 (pt)
ES (3) ES2166111T3 (pt)
PT (3) PT867184E (pt)
WO (1) WO1997002813A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
PT991409E (pt) * 1997-08-01 2002-06-28 Elan Corp Plc Composicoes farmaceuticas de libertacao controlada contendo tiagabina
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
ATE390133T1 (de) * 2000-06-26 2008-04-15 Warner Lambert Co Gabapentinanaloga für schlafstörungen
EP1389091A1 (en) * 2001-05-21 2004-02-18 H. Lundbeck A/S Granular preparations of gaboxadol
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) * 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
JP5380930B2 (ja) * 2007-07-24 2014-01-08 大正製薬株式会社 睡眠改善剤
ES2876350T3 (es) * 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
DK3274331T3 (da) 2015-03-24 2020-03-23 H Lundbeck As Fremstilling af 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
AU2019398025B2 (en) 2018-12-14 2025-03-27 Raimondo Fazio Martial arts training device
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
KR102773472B1 (ko) * 2021-05-21 2025-02-27 한국식품연구원 구릿대 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
US20240269206A1 (en) * 2021-08-11 2024-08-15 Psyched Wellness Ltd. Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) * 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Also Published As

Publication number Publication date
EP0867184B1 (en) 2001-10-24
AU6613796A (en) 1997-02-10
DE19525598A1 (de) 1997-01-16
WO1997002813A1 (en) 1997-01-30
DE69616376D1 (de) 2001-11-29
EP0867178A1 (en) 1998-09-30
DE69616333T2 (de) 2002-07-04
DE69616376T2 (de) 2002-06-27
DE19525598C2 (de) 1997-09-25
AU723954B2 (en) 2000-09-07
ATE207352T1 (de) 2001-11-15
ES2165990T3 (es) 2002-04-01
CA2226582C (en) 2008-02-19
DE69616375D1 (de) 2001-11-29
CL2003002785A1 (es) 2005-04-08
EP0867184A1 (en) 1998-09-30
PT867184E (pt) 2002-04-29
DK0867184T3 (da) 2002-02-18
PT840601E (pt) 2002-04-29
DK0867178T3 (da) 2002-02-18
ES2166111T3 (es) 2002-04-01
ATE207356T1 (de) 2001-11-15
DK0840601T3 (da) 2002-02-18
EP0867178B1 (en) 2001-10-24
US5929065A (en) 1999-07-27
CA2226582A1 (en) 1997-01-30
JP3754705B2 (ja) 2006-03-15
EP0840601A1 (en) 1998-05-13
ES2166110T3 (es) 2002-04-01
JPH11509194A (ja) 1999-08-17
DE69616375T2 (de) 2002-07-11
DE69616333D1 (de) 2001-11-29
EP0840601B1 (en) 2001-10-24
JP2009057382A (ja) 2009-03-19
JP2005047925A (ja) 2005-02-24
ATE207349T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
BR9912501A (pt) Tratamento de distúrbios hiperproliferativos
NO970067D0 (no) Nytt farmasöytisk preparat for smertebehandling
BR9306226A (pt) Composiçao de cura de feridas e tratamento de distúrbios fibróticos e método para a sua preparaçao
EA200101089A1 (ru) Новый способ лечения
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
ES2173977T3 (es) Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
PT774961E (pt) Utilizacao de selegilina para o tratamento de doencas epilepticas
BR9708037A (pt) Método para o tratamento de abuso de substância
EP0904094A4 (en) TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.